| __timestamp | Ionis Pharmaceuticals, Inc. | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 241751000 | 117418000 |
| Thursday, January 1, 2015 | 322292000 | 102526000 |
| Friday, January 1, 2016 | 344320000 | 105386000 |
| Sunday, January 1, 2017 | 374644000 | 110188000 |
| Monday, January 1, 2018 | 1820000 | 121544000 |
| Tuesday, January 1, 2019 | 4000000 | 127930000 |
| Wednesday, January 1, 2020 | 12000000 | 148917000 |
| Friday, January 1, 2021 | 11000000 | 440760000 |
| Saturday, January 1, 2022 | 14000000 | 540517000 |
| Sunday, January 1, 2023 | 9133000 | 435577000 |
| Monday, January 1, 2024 | 11215000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, cost efficiency is a critical factor for success. Jazz Pharmaceuticals plc and Ionis Pharmaceuticals, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Jazz Pharmaceuticals has demonstrated a remarkable increase in cost efficiency, with their cost of revenue peaking at approximately 540 million in 2022, a staggering 360% increase from 2014. In contrast, Ionis Pharmaceuticals experienced a significant decline, with their cost of revenue dropping by nearly 96% from its 2017 peak to 2023. This divergence highlights Jazz's strategic prowess in managing production costs, while Ionis faces challenges in maintaining cost efficiency. As the pharmaceutical industry continues to evolve, these trends underscore the importance of strategic financial management in sustaining competitive advantage.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Jazz Pharmaceuticals plc
Cost of Revenue Trends: Novo Nordisk A/S vs Jazz Pharmaceuticals plc
Novartis AG vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sanofi and Ionis Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Zoetis Inc. vs Jazz Pharmaceuticals plc
Cost of Revenue: Key Insights for Jazz Pharmaceuticals plc and CRISPR Therapeutics AG
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Xenon Pharmaceuticals Inc.
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Ionis Pharmaceuticals, Inc. vs Alkermes plc
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.